Avoid common mistakes on your manuscript.
Correction to: Blair, H.A. Elafibranor: First Approval. Drugs (2024). https://doi.org/10.1007/s40265-024-02075-8
Section 2.1 Pharmacodynamics. The third sentence of the second paragraph, which currently reads:
Although the in vitro pharmacology studies detected PPAR-gamma activation by elafibranor and GFT1007, animal toxicology studies demonstrated no adverse effects associated with activation of PPAR-γ [6].
Should read:
Although the in vitro pharmacology studies detected PPAR-γ activation by elafibranor and GFT1007, animal toxicology studies demonstrated no adverse effects associated with activation of PPAR-γ [6].
Table: Features and Properties of Elafbranor. WHO ATC codes, which currently reads:
A05AX (Other Drugs for Bile Therapy)
Should read:
A05AX06 (Other Drugs for Bile Therapy)
Section 3 Current Status. The reference for the last sentence should be [8] not [5]
Elafibranor received a positive opinion in the EU in July 2024 for the treatment of PBC [8].
The original article has been corrected.
Data availability
Not applicable.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blair, H.A. Correction: Elafibranor: First Approval. Drugs (2024). https://doi.org/10.1007/s40265-024-02088-3
Accepted:
Published:
DOI: https://doi.org/10.1007/s40265-024-02088-3